In the BioHarmony Drug Report Database
Entrectinib
Rozlytrek (entrectinib) is a small molecule pharmaceutical. Entrectinib was first approved as Rozlytrek on 2019-08-15. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat neoplasms and non-small-cell lung carcinoma. Rozlytrek’s patents are valid until 2038-07-18 (FDA).
Trade Name
|
Rozlytrek |
|---|---|
Common Name
|
entrectinib |
ChEMBL ID
|
CHEMBL1983268 |
Indication
|
neoplasms, non-small-cell lung carcinoma |
Drug Class
|
Tyrosine kinase inhibitors: tropomyosin receptor kinase (TRK) inhibitors |
Image (chem structure or protein)